While the metabolic consequences of Cpt1a inhibition may have exacerbated infection-related end-organ dysfunction and contributed to mortality in etomoxir-treated, infected animals, the increase in bacteria recovered from the lungs and extrapulmonary organs of these mice suggests a defect in innate immune control of the bacterial infection. Here, CPT1A is linked to bacterial infectious disease.